Business
MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026
NEW YORK, January 12, 2026--MindMed Announces Rebrand to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026
About this update from Definium Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":5693,"height":1188,"url":"https://media.zenfs.com/en/business-wire.com/cb181c22d0aa77ccaa29d25f3a5ff2be"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/VLrwefjDZDUplI9mfMS.9g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIwMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/cb181c22d0aa77ccaa29d25f3a5ff2be","width":960,"height":200},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/lp9UI__icUJRKAQDzaZ2tw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/cb181c22d0aa77ccaa29d25f3a5ff2be","width":1200,"height":250}},"lazy":false},{"type":"text","content":"Topline Data from Three Phase 3 Studies Evaluating DT120 Orally Disintegrating Tablet (ODT) for GAD and MDD Expected in 2026: Voyage in 2Q, Panorama in 2H, and Emerge Mid-Year","length":175,"tagName":"p","attribs":{}},{"type":"text","content":"Company Presenting at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, at 2:15 PM PST","length":112,"tagName":"p","attribs":{}},{"type":"text","content":"Company Shares Will Trade Under New Nasdaq Ticker Symbol "DFTX"","length":73,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, January 12, 2026--(BUSINESS WIRE)--Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) (the "Company" or "Definium") unveiled its new brand today, marking a decisive step forward as the company leads psychiatry toward a transformation built on strong clinical evidence, scientific rigor, and the ambition to evolve the treatment paradigm for mental health. Definium is developing innovative, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction.","length":628,"tagName":"p"},{"type":"text","content":"Over the past several years, the Company has offered a clear, differentiated vision and executed with discipline, positioning it as a leader in psychiatric drug development. Definium Therapeutics demonstrates this clarity and consistency, representing a confident step forward that best reflects what the Company has become and the enormous potential of what it's buildin...